Owen Mumford Achieves B Corp Certification

Owen Mumford, a global leader in the design, manufacture, and advancement of medical devices, today announced it has been awarded B Corp certification after demonstrating strict compliance to the rigorous requirements of this hard-to-achieve, globally-recognized mark.

Owen Mumford, which established its sustainability program in 2014 and has formally committed to the UN’s Sustainable Development Goals (SDGs), now joins a highly respected community of for-profit businesses that are applying growth and profit to the positive gain of the environment and external communities, as well as employees.

B Corp is the standard for a new generation of aspirational brands who are helping to define the future of business in a responsible way. There are now 4,010 B Corps in 77 countries and 153 industries, and over 100,000 companies manage their impact with the B Impact Assessment and the SDG Action Manager. The B Corp community in the UK, representing a broad cross-section of industries and sizes, comprises over 400 companies.

B Corp certification assesses five areas of impact: governance, community, workers, environment and customers. “Our social and environmental responsibilities have always been high on the agenda at Owen Mumford,” said Jarl Severn, CEO at Owen Mumford. “Submitting ourselves to the rigorous process of B Corp certification is a natural development of our core principles. Companies like ours that operate in the medical sector are used to the demands of a tightly regulated environment. We believe that it is not enough simply to state ethical and environmental aspirations, but it is also critical to achieving a recognized certification. After all, our marketplaces are reliant on top ethical standards to protect environments, professionals and patients. B Corp provides a solid benchmark for continually improving what we do in our business, in the global communities that we are part of and the ones where can make a positive impact.”

Owen Mumford has pioneered the design and manufacture of medical devices such as self-injection, blood sampling, and drug delivery for almost 70 years and is the first such company to become part of the B Corp community. This milestone firmly underscores its commitment to making a positive difference on social and environmental impact.

Kate Sandle, Director of Programmes and Engagement of B Lab UK, says “We are delighted to welcome Owen Mumford to the B Corp community. This is a movement of companies who are committed to changing how the business operates and believe business really can be a force for good. We know that Owen Mumford is going to be a fantastic addition to the community and will continue driving the conversation forward. Welcoming Owen Mumford is an exciting moment because it has an opportunity to lead the way within the medical device industry.”

B Corp certification must be renewed every three years to ensure continuing compliance to the stringent requirements.

Medical Device News Magazinehttps://infomeddnews.com
Our publication is dedicated to bringing our readers the latest medical device news. We are proud to boast that our subscribers include medical specialists, device industry executives, investors, and other allied health professionals, as well as patients who are interested in researching various medical devices. We hope you find value in our easy-to-read publication and its overall purpose and objectives! Medical Device News Magazine is a division of PTM Healthcare Marketing, Inc. Pauline T. Mayer is the managing editor.

More News!

Data from clinical studies of STK-001 demonstrated clinical benefit for patients ages 2 to 18 years old, including reductions in seizures and improvements in cognition and behavior that support the potential for disease modificatio. Analysis of 72 patients treated in STK-001 clinical trials suggests that higher STK-001 drug exposure in brain leads to greater seizure reductions. Two-year data from the longest prospective natural history study of Dravet syndrome showed that, on average, patients experienced no meaningful improvement in convulsive seizure frequency and exhibited widening gaps in cognition and behavior despite treatment with the best available anti-seizure medicines.
"Exact Sciences is looking forward to presenting new evidence at SABCS that adds important perspectives to treating breast cancer patients and showing that some patients may be able to de-escalate treatments and still have positive outcomes," said Dr. Rick Baehner, Chief Medical Officer, Precision Oncology, Exact Sciences. "Every year, we build upon the precedent set by the Oncotype DX Breast Recurrence Score® test and its prognostic and predictive abilities to determine the chemotherapy benefit for specific breast cancer patients. We are pleased to see authorities expanding access to this test as we continue to develop key evidence in collaboration with some of the world's most prestigious, breast cancer-focused organizations."
Clozapine has been established as the most effective antipsychotic medication for treatment-resistant schizophrenia. However, it is significantly underutilized mainly due to the risk of developing agranulocytosis and the need to frequently monitor the absolute neutrophil count (ANC).
Dagi-Ben Noon, CEO of Inspira Technologies, reflects on the partnership's significance: "By Integrating our technology to oxygenate blood directly with Ennocure's infection prevention solutions, we are focusing on potentially improving patient outcomes in ICUs and paving the way for safer, more effective life-support treatments. This collaboration is expected to accelerate the development and broaden the implementation of our advanced technology."
The findings suggest that the novel, non-invasive genomic test can help physicians guide next steps for these patients, enabling them to potentially avoid unnecessary invasive procedures or accelerate time to appropriate treatment.

By using this website you agree to accept Medical Device News Magazine Privacy Policy